Cuddly Aflac Social Robot Ducks Aim to Comfort Children With SCD

The supplemental insurance provider Aflac is expanding its “My Special Aflac Duck” social robot program to benefit children with sickle cell disease (SCD). Healthcare professionals and nonprofit organizations can order the life-sized robotic companion for free for children ages 3 and up who have cancer or SCD.

Rare Disease Day Events Bring Awareness, Equity to Patients

Since 2008, Rare Disease Day — the last day of February — has brought together patients, caregivers, family members, friends, and advocates from around the world to raise awareness and improve equity for the more than 7,000 known rare diseases that affect more than 300 million people. In 2022, the…

Adakveo Available in UK’s NHS for Patients 16 and Older

Adakveo (crizanlizumab), by Novartis, is now available on the U.K.’s National Health Service (NHS) for sickle cell disease (SCD) patients 16 and older. The new treatment, which is delivered by an into-the-vein infusion, can be used alone or as an add-on to hydroxyurea to help reduce the frequency of…

Eligible Patients in UK Granted Early Access to Oxbryta

Oxbryta (voxelotor), a daily oral therapy for hemolytic anemia associated with sickle cell disease (SCD), is now available to eligible patients in the U.K. under an early access program. It received a positive scientific opinion by the U.K.’s Medicines and Healthcare products Regulatory Agency (MHRA) under the Early…

Pandemic Leading to Fewer Hospital Stays, but More Severe Crises

Fewer adults and children with sickle cell disease (SCD) have sought medical care for disease-related events during the COVID-19 pandemic, resulting in lower hospitalization rates, but longer hospital stays, according to data collected from a specialty center in Southern California that cares for a large number of SCD patients.